Vaccinia Virus (WR) F9L Protein with C-terminal Histidine Tag, Recombinant from baculovirus

Catalog No. NR-2626

For research use only. Not for human use.

Contributor:

Gary H. Cohen, Ph.D., Professor and Chair, Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania and Roselyn J. Eisenberg, Ph.D., Professor, Department of Pathobiology, Head, Laboratories of Microbiology and Immunology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Product Description:

NR-2626 is a recombinant form of the F9L membrane glycoprotein (F9Lt; residues 1 to 175, C-terminal histidine-tagged) of the Western Reserve (WR) strain of vaccinia virus. The full length F9L protein is 212 residues (GenPept: P24361).[1] NR-2626 was produced in cabbage looper *(Trichoplusia ni)* insect larvae using a baculovirus expression vector system[2] and was purified using nickel affinity chromatography. The predicted protein sequence is shown in Table 1 below. Non-vaccinia virus residues are underlined.

Material Provided:

Each vial contains approximately 1.0 mg of NR-2626 in 12.5 mM phosphate buffer (pH 7.0) containing 75 mM NaCl/50% glycerol (v/v). The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-2626 was packaged aseptically in cryovials. The product is provided on dry ice and should be stored at -20°C or colder immediately upon arrival. Repeated freeze-thaw cycles of this product should be avoided.

Functional Activity:

NR-2626 was demonstrated to be functionally active based on its reactivity with rabbit polyclonal antibody to F9L.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Vaccinia Virus (WR) F9L Protein with C-terminal Histidine Tag, Recombinant from baculovirus, NR-2626."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to negotiate a license. U.S. Government contractors may need a license before first commercial sale.

References:

1. Roseman, N. A. and M. B. Slabaugh. "The Vaccinia Virus HindIII F Fragment: Nucleotide Sequence of the Left 6.2 Kb." Virology 178 (1990): 410–418. PubMed: 2219701.
2. PERLXpress™, Chesapeake Protein Expression and Recovery Labs (PERL).

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org
800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org

Product Information Sheet for NR-2626

Table 1 - Predicted Protein Sequence					
1	DHMAETKEFK	TLYNLFIDSY	LQKLAQHSIP	TNVTCAIHIG	EVIGQFKNCA
51	LRITNKCMSN	SRLSFTLMVE	SFIEVISLLP	EKDRRAIAEE	IGIDLDDVPS
101	AVSKLEKNCN	AYAEVNNIID	IQKLDIGECS	APPGQHMLLQ	IVNTGSAEAN
151	CGLQTIVKSL	NKIYVPPIIE	NRLPYYDHHH	HHH	

Non-vaccinia virus amino acids are underlined.

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org